-
Mashup Score: 6Tumor Board Tuesday 2023 Conversations - 6 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865) - 7 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Tumor Board Tuesday 2023 Conversations - 7 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865) - 7 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Tumor Board Tuesday 2023 Conversations - 7 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6Tumor Board Tuesday 2023 Conversations - 7 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 7
8500 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy have a promising efficacy in resectable non-small-cell lung cancer (NSCLC), yet the period of neoadjuvant immunochemotherapy is undetermined. This phase II study compared the efficacy and safety of two cycles with three cycles of neoadjuvant sintilimab plus chemotherapy in resectable stage IB-IIIA NSCLC. Methods: This randomized, open-label phase II trial recruited patients aged 18 or older with histologically confirmed, treatment-naïve, American Joint Committee on Cancer-defined stage IB-IIIA, resectable NSCLC. Eligible patients were randomly assigned to two or three cycles of neoadjuvant treatment with intravenous sintilimab (200 mg) plus carboplatin (area under curve 5) and nab-paclitaxel (260mg/m2, for squamous) or pemetrexed (500mg/m2, for non-squamous) on day 1 of three-week cycle. After surgical resection, patients received totally four doses of perioperative immunochemotherapy, followed by one-ye
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@Latinamd @ShrutiPatelMD @TumorBoardTues @IntegrityCE @JanssenUS @AstraZeneca @MPishvaian @JohnEbbenMDPhD @FordePatrick @jennifermarksmd @minaseconomides @LVaezi @KE_Gallaway @safichintan @KellyMezaMD @random_mommy @MatthewKurianMD @guicorreiamd @PathologyPat @KevinCalsina @EshaJ15 @OncogeneCancer @fgrazz @crisbergerot @esinghimd @chungryul_oh @MomaVelez11 @SamuelKareffMD @FawziAbuRous @BRoseMDMPH @bjork5 @HamediZahra @DrJNaidoo @RogerZhuMD @cbaldotto @RohitBanwar @JineshGheeya @COlazagasti @PatelOncology @APassaroMD @azza64 @g_mountzios @drMaryOBr @LungCancerFaces @susila55 @SewantiLimaye @NReguart @BrendonStilesMD @triparnasen @ReinaHonts Good point, excellent point. Data from a study conducted in Asia showed that at least three cycles are needed. https://t.co/IB4OPRrUbx #TumorBoardTuesday
-
-
Mashup Score: 5Tumor Board Tuesday 2023 Conversations - 8 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 4Tumor Board Tuesday 2023 Conversations - 8 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TumorBoardTues: #TumorBoardTuesday B4⃣we dive into this🗣️get your🧠warmed up with these2⃣poll📊❓s Free #CME🔗 https://t.co/GzqzvikHrp Que…
-
-
Mashup Score: 4Tumor Board Tuesday 2023 Conversations - 8 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Partners & KOLsTweet
RT @TumorBoardTues: #PreTest Q1️⃣ #TumorBoardTuesday Free #CME https://t.co/Gzqzvik9BR ➡️B4 @AmandaNizamMD & @YuWeiChenMD🗣️Tx for #rcc aft…